press releases

Date Title Teaser
Date Title  
05/09/24
- First patient start (cell collection) for LYFGENIA completed – - 15 patient starts to date in 2024 (11 ZYNTEGLO, 3 SKYSONA, 1 LYFGENIA); 85 to 105 patient starts anticipated across the portfolio in 2024 - - First quarter 2024 net revenue of $18.6 million - - Management to host conference call
 
05/06/24
SOMERVILLE, Mass. --(BUSINESS WIRE)--May 6, 2024-- bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss first quarter 2024 results and business updates on May 9 , at 8:00 a.m. ET . To participate in the conference call, please dial +1 (800) 715-9871 (
 
05/06/24
SOMERVILLE, Mass. --(BUSINESS WIRE)--May 6, 2024-- bluebird bio, Inc. (Nasdaq: BLUE) announced today that it has completed the first commercial cell collection for LYFGENIA (lovotibeglogene autotemcel), a one-time gene therapy for the treatment of sickle cell disease in patients with a history of
 
04/26/24
SOMERVILLE, Mass. --(BUSINESS WIRE)--Apr. 26, 2024-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that it received a notice (the “notice”) on April 24, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Annual Report on Form 10-K for the
 
04/11/24
SOMERVILLE, Mass. --(BUSINESS WIRE)--Apr. 11, 2024-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of 102,700 restricted stock units (“RSUs”) to twelve newly hired employees with a grant date of April
 
03/26/24
- Cash runway through Q1 2026 following announcement of a $175 million term loan facility with Hercules Capital - - 9 patient starts to date in 2024 (7 ZYNTEGLO, 2 SKYSONA); 85 to 105 patient starts anticipated across the portfolio in 2024 - - First government outcomes-based agreement for sickle
 
03/25/24
SOMERVILLE, Mass. --(BUSINESS WIRE)--Mar. 25, 2024-- bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss fourth quarter and 2023 annual results and business updates on March 26, 2024 , at 8:00 a.m. ET . To access the live conference call via telephone,
 
03/18/24
- Funding expected to extend the Company’s cash runway beyond the next 24 months - - First tranche of $75 million was drawn upon closing; the Company will be eligible to draw an additional $50 million subject to achievement of commercial milestones - SOMERVILLE, Mass. --(BUSINESS WIRE)--Mar.
 
03/11/24
SOMERVILLE, Mass. --(BUSINESS WIRE)--Mar. 11, 2024-- bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio”) today announced it has signed its first Medicaid outcomes-based agreement for LYFGENIA™ (lovotibeglogene autotemcel, also known as lovo-cel) with the state of Michigan .
 
01/08/24
Significant momentum behind LYFGENIA launch with 35 Qualified Treatment Centers accepting patient referrals and payer agreements in place covering approximately 200 million U.S. lives Anticipate 85 to 105 patient starts (cell collections) across commercial portfolio in 2024 with first patient start
 
01/02/24
SOMERVILLE, Mass. --(BUSINESS WIRE)--Jan. 2, 2024-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that Andrew Obenshain , chief executive officer, bluebird bio, will present a corporate update at the 42 nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 , at 10:30am PT /
 

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. bluebird bio disavows any obligation to update the information contained in such press releases after the date of their issuance.